» Articles » PMID: 35771165

The Gastric Cancer Registry: A Genomic Translational Resource for Multidisciplinary Research in Gastric Cancer

Abstract

Background: Gastric cancer is a leading cause of cancer morbidity and mortality. Developing information systems which integrate clinical and genomic data may accelerate discoveries to improve cancer prevention, detection, and treatment. To support translational research in gastric cancer, we developed the Gastric Cancer Registry (GCR), a North American repository of clinical and cancer genomics data.

Methods: Participants self-enrolled online. Entry criteria into the GCR included the following: (i) diagnosis of gastric cancer, (ii) history of gastric cancer in a first- or second-degree relative, or (iii) known germline mutation in the gene CDH1. Participants provided demographic and clinical information through a detailed survey. Some participants provided specimens of saliva and tumor samples. Tumor samples underwent exome sequencing, whole-genome sequencing, and transcriptome sequencing.

Results: From 2011 to 2021, 567 individuals registered and returned the clinical questionnaire. For this cohort 65% had a personal history of gastric cancer, 36% reported a family history of gastric cancer, and 14% had a germline CDH1 mutation. 89 patients with gastric cancer provided tumor samples. For the initial study, 41 tumors were sequenced using next-generation sequencing. The data was analyzed for cancer mutations, copy-number variations, gene expression, microbiome, neoantigens, immune infiltrates, and other features. We developed a searchable, web-based interface (the GCR Genome Explorer) to enable researchers' access to these datasets.

Conclusions: The GCR is a unique, North American gastric cancer registry which integrates clinical and genomic annotation.

Impact: Available for researchers through an open access, web-based explorer, the GCR Genome Explorer will accelerate collaborative gastric cancer research across the United States and world.

References
1.
McCarty C, Chisholm R, Chute C, Kullo I, Jarvik G, Larson E . The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics. 2011; 4:13. PMC: 3038887. DOI: 10.1186/1755-8794-4-13. View

2.
Xia L, Van Hummelen P, Kubit M, Lee H, Bell J, Grimes S . Whole genome analysis identifies the association of TP53 genomic deletions with lower survival in Stage III colorectal cancer. Sci Rep. 2020; 10(1):5009. PMC: 7081316. DOI: 10.1038/s41598-020-61643-6. View

3.
Champiat S, Ferte C, Lebel-Binay S, Eggermont A, Soria J . Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014; 3(1):e27817. PMC: 3937193. DOI: 10.4161/onci.27817. View

4.
Brown S, Warren R, Gibb E, Martin S, Spinelli J, Nelson B . Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014; 24(5):743-50. PMC: 4009604. DOI: 10.1101/gr.165985.113. View

5.
Greytak S, Engel K, Bass B, Moore H . Accuracy of Molecular Data Generated with FFPE Biospecimens: Lessons from the Literature. Cancer Res. 2015; 75(8):1541-7. PMC: 4636024. DOI: 10.1158/0008-5472.CAN-14-2378. View